louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05313607: Effect of Plyometric Exercises on Upper Extremity Function in Children With Unilateral Cerebral Palsy
Official title: Effect of Plyometric Exercises on Upper Extremity Function in Children With Unilateral Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sports Physical Therapy
Keywords: plyometric exercises
Unilateral Cerebral Palsy
cerebral pslay
hand grip strength
upper extremity function
selective motor control
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-04-06
Enrollment: 40
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Plyometric training includes muscle contraction that moves rapidly from the eccentric to the concentric phase of movement while using proper biomechanics. It is an effective neuromuscular stimulus that can improve motor functions of children with CP. In plyometric training, muscles exert maximum force in short intervals of time, with the goal of increasing power.

Detailed description: This is a prospective double-masked randomized controlled trial.

Eligibility criteria: Inclusion Criteria:

- spastic hemiplegia

Exclusion Criteria:

- fixed deformities

Primary outcomes:
measure: Upper extremity function
timeFrame: after 3 successive months
measure: Hand grip strength
timeFrame: after 3 successive months
Secondary outcomes:
measure: Selective motor control
timeFrame: after 3 successive months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Amira Mahmoud Abd-elmonem
Study officials:
affiliation: Cairo university, faculty of physical therapy
name: walaa A El-nabie, Phd
role: STUDY_CHAIR
affiliation: Cairo university, faculty of physical therapy
name: Hazem A Ali, Phd
role: STUDY_DIRECTOR
References:
Clinical trial NCT05909007: Post-operative Thoracic Epidural Analgesia and Incidence of Major Complications: a Large Retrospective Dual Center Experi-ence
Official title: Post-operative Thoracic Epidural Analgesia and Incidence of Major Complications: a Large Retrospective Dual Center Experi-ence
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuropathic Pain
Chronic Pain
Thoracic Cancer
Lead sponsor: AHEPA University Hospital
Sponsor class: OTHER
Collaborators: name: Royal Brompton & Harefield NHS Foundation Trust
First posted: 2023-06-18
Enrollment: 1145
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients underwent major thoracic surgery and lung transplantation. ASA status 1-3

Brief summary: A retrospective observational dual center study investigating side effects and major complications after thoracic epidural insertion according to local safety protocols.

Detailed description: Abstract: (1) Background: Thoracic epidural analgesia is considered the gold standard in post-operative pain management following thoracic surgery. This study was designed to explore the safety of thoracic epidural analgesia and to quantify the incidence of its post-operative side-effects in patients undergoing thoracotomy for major surgery, such as resection of lung malignancies and lung transplantation. (2) Methods: This is a retrospective, dual-center observa-tional study implementing patients that underwent major thoracic surgery including lung trans-plantation and received concurrent placement of thoracic epidural catheters for postoperative an-algesia. An electronic system of referral and documentation of complications was used, and information was retrieved from our electronic critical care charting system. Side effects such as nausea and vomiting , itching, catheter related issues and also major complications such as epidural haematoma, abscess, or permanent nerve damage were investigated.

The study aims to highlight the importance of a solid documentation and recording system alongside with the implementation of safety protocols.

Eligibility criteria: Inclusion Criteria: 1. All patients undergoing major thoracic surgery ASA1-3 2. All patients undergoing lung transplantation

Exclusion Criteria: 1. Active bleeding 2. Coagulopathy 3. High inflammatory markers 4. SIRS 5. Lack of patients' consent for throracic epidural insertion

-

Primary outcomes:
measure: incidence of major complications
timeFrame: 3 YEARS
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Ahepa University Hospital
Study officials:
References:
Clinical trial NCT02391207: Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence
Official title: Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence: Validation on Intention-to-treat Analysis of a IOUS-guided Approach
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Secondary Malignant Neoplasm of Liver
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2015-03-18
Enrollment: 50
Sex: ALL
Minimum age (years): 28
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patiens undergoing hepatectomy for primary and secondary liver tumors

Brief summary: Major hepatectomies are generally selected for tumors involving the hepatic vein (HV) at the caval confluence (CC). As alternative, HV reconstruction has been proposed. The present study aimed to evaluate the feasibility and safety of a HV-sparing policy guided by intraoperative ultrasonography (IOUS) in a cohort of patients having at least one colorectal liver metastasis (CLM) in contact with a HV at CC. HV section can be avoided in the large majority of cases thanking to CLMs detachment or to HV partial resection or reconstruction: this policy seems feasible, safe, reduces the need of major hepatectomies, and oncologically provides an adequate local control.


Eligibility criteria: Inclusion Criteria:

* diagnosis of at least one CLM in contact with HV at caval confluence and HV patency at preoperative imaging
* at least 6 months of follow-up after surgery

Exclusion Criteria:

* suspected or ascertained thrombosis or full tumoral involvement of HV at preoperative imaging
* portal pedicle infiltration and/or thrombosis
* unresectability at laparotomy for any extra-hepatic or intrahepatic reason not related to tumor-vessel relations

Primary outcomes:
measure: the safety of HV-sparing surgery in terms of operative mortality and morbidity
timeFrame: within 30-90 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Department of Hepatobiliary and General Surgery, Humanitas Research Hospital, University of Milan
state: Milan
Study officials:
affiliation: Department of Hepatobiliary and General Surgery, University of Milan, Humanitas Research Hospital, Rozzano, Milan, Italy
name: Guido Torzilli, MD,PhD,FACS
role: STUDY_DIRECTOR
affiliation: Department of Hepatobiliary and General Surgery, University of Milan, Humanitas Research Hospital, Rozzano, Milan, Italy
name: Fabio Procopio, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06352307: Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy
Official title: Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Arrhythmogenic Cardiomyopathy
Keywords: Arrhythmogenic cardiomyopathy
Prognostic factors
Lead sponsor: First Affiliated Hospital Xi'an Jiaotong University
Sponsor class: OTHER
First posted: 2024-04-08
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with ACM at all centers including The First Affiliated Hospital of Xi'an Jiaotong University.

Brief summary: This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Detailed description: This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years old.
* The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
* Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion Criteria:

* Incomplete clinical data.
* Do not agree to the inclusion or refuse to authorize the informed consent.

Primary outcomes:
measure: Change in the incidence of mortality rate
timeFrame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: First Affiliated Hospital of Xi'an Jiantong University
state: Shaanxi
Study officials:
affiliation: First Affiliated Hospital Xi'an Jiaotong University
name: Yang Yan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02900807: CT-scan Airways Mensuration - Correlation to External Measurements
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intubation
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-14
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient scheduled for a CT-scan including the airways and the upper part of the chest until the hull

Brief summary: Oro-tracheal intubation is performed daily in anesthesia and in the ICU. When a patient is intubated, the endotracheal tube must be inserted into the trachea to the right depth. If the tube is not deep Inserted enough there is a risk of accidental extubation and trauma to the vocal cords by the balloon. If the tube is inserted too far there is a risk of selective intubation into the right or left mainstem bronchus, which can lead to contralateral lung atelectasis and hypoxemia.

The purpose of this study is to determine whether there is a correlation between the measurement of the airway of an adult population and criteria that would be easily accessible in daily clinical practice: the height of the patient and the size of their feet.


Eligibility criteria: Inclusion Criteria:

* patient scheduled for a CT-scan including the airways and the upper part of the chest at least until the carina
* patient size between between 150 cm and 195 cm

Exclusion Criteria:

* significant deformity of the cervical spine to accurately measure the size of patients (kyphoscoliosis...)
* impossibility of reliably know the size of the patient
* history of pharyngo-laryngeal surgery resulting in a significant deformity or a loss of anatomical landmarks incompatible with reliable measurements between dental arches and glottic plan (total laryngectomy...)
* history of lung surgery not allowing reliable location of the carina (pneumonectomy, double-lung transplant)

Primary outcomes:
measure: size of the patients and/or size of their feet
timeFrame: Duration of the CT-scan : about 1 hour
measure: measurement of patients' airways
timeFrame: Duration of the CT-scan : about 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschild
Study officials:
affiliation: Fondation OPH A de Rothschild
name: Guillaume Taylor, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03292107: Study on Management Thrombosis in Greek Cancer Patients
Official title: Study on Management Thrombosis in Greek Cancer Patients (GMaT - Greek Management Thrombosis)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombosis
Lead sponsor: Hellenic Society of Medical Oncology
Sponsor class: OTHER
First posted: 2017-09-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with solid tumors under anticoagulation regime, for prophylaxis or treatment.

Brief summary: Study on Management Thrombosis in Greek cancer patients

Detailed description: The approach that Medical Oncologists encounter the prospect of a coagulation event occurrence in cancer patients.

Eligibility criteria: Inclusion Criteria

* All patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline.
* Age ≥ 18 years
* Signed informed consent

Exclusion Criteria

* Initiation of anticoagulation therapy before the initiation of the study in 2016
* Age \<18 years
* No signed informed consent

Primary outcomes:
measure: The clinical practice for patients under anticoagulation regime
timeFrame: 1 YEAR
Secondary outcomes:
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Hellenic Society of Medical Oncology
Study officials:
affiliation: Hellenic Society of Medical Oncology
name: Ioannis Varthalitis, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Christopoulou A, Ardavanis A, Papandreou C, Koumakis G, Papatsimpas G, Papakotoulas P, Tsoukalas N, Andreadis C, Samelis G, Papakostas P, Aravantinos G, Ziras N, Souggleri M, Kalofonos C, Samantas E, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Bokas A, Grivas A, Tripodaki ES, Varthalitis I, Timotheadou E, Boukovinas I. Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence. Oncol Lett. 2022 Apr;23(4):115. doi: 10.3892/ol.2022.13235. Epub 2022 Feb 9.
Clinical trial NCT00269607: Naltrexone Implants as Relapse Prevention
Official title: Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Opioid Dependency
Keywords: Substance abuse
Treatment
Relapse prevention
opioid antagonist
Lead sponsor: University of Oslo
Sponsor class: OTHER
First posted: 2005-12-23
Enrollment: 12
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. Participants in the naltrexone experimental group are prematched in a pairwise fashion with other patients who do not want a naltrexone implant during the first six months after ending inpatient treatment, but who reiceive treatment as usual (TAU) from the Norwegian healthcare system.

The hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up.

We also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.


Eligibility criteria: Inclusion Criteria:

* soon to complete inpatient treatment for opioid addiction
* living in southern Norway

Exclusion Criteria:

* psychosis / major depression, currently not treated
* pregnancy
* liver enzymes: ASAT or ALAT \> threefold above upper boundary
* maintenance treatment with methadone or buprenorphine

Primary outcomes:
measure: Primary Outcomes: drug use at 6(12/18)months by self report, hair analysis; days in work or education, number of drug-free friends at 6 (12/18)months by self report
Secondary outcomes:
measure: Secondary Outcomes: depression at 6(12/18)months by BDI and Hopkins SCL-25; quality of life at 6(12/18)months by EuropASI
Other outcomes:
Locations:
Study officials:
affiliation: Unit for addiction medicine, Institute of psychiatry, University of Oslo
name: Helge Waal, professor
role: STUDY_DIRECTOR
References:
citation: Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, Kristensen O, Waal H. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010 Sep;105(9):1633-9. doi: 10.1111/j.1360-0443.2010.03031.x.
Clinical trial NCT05335707: Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Official title: Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Pilot Trial
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Urinary Bladder Cancer
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2022-04-19
Enrollment: 0
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 65 and older with biopsy-proven muscle-invasive bladder cancer planned for neoadjuvant chemotherapy and radical cystectomy.

Brief summary: This single arm pilot study will evaluate the feasibility and acceptability for perioperative Comprehensive Geriatric Assessment (CGA) and CGA-directed supportive and restorative care for patients with muscle-invasive bladder cancer who are planned to undergo preoperative chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
* Males and females age ≥ 65 years
* Diagnosis/disease status
* Histologically proven muscle-invasive bladder cancer (MIBC) without metastatic disease.
* Patients planning to undergo neoadjuvant chemotherapy and radical cystectomy for MIBC.
* Treatment with investigational systemic therapy is permitted if participants will be receiving chemotherapy as part of their treatment plan

Exclusion Criteria:

* Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
* Any other known invasive malignancy within previous 2 years with the following EXCEPT: low grade prostate cancer on active surveillance, chronic lymphocytic leukemia CLL on surveillance / observation, non-melanoma skin cancers

Primary outcomes:
measure: Develop a geriatric oncology assessment clinic and workflows
timeFrame: 12 months
Secondary outcomes:
measure: Test feasibility, acceptability, and preliminary impact
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03708107: Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points
Official title: Short Term Effects in Pressure-pain Threshold of Percutaneous Galvanic Microcurrent Versus Ischemic Compression in the Trapezius Trigger Points
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myofascial Trigger Point Pain
Keywords: galvanic current
electrolysis
myofascial trigger point
percutaneous microelectrolysis
dry needling
ischemic compression
Lead sponsor: Instituto Universitario de Ciencias de la Salud Fundación H.A. Barceló
Sponsor class: OTHER
First posted: 2018-10-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Percutaneous Microelectrolysis ® (MEP®) is a technique that employs a galvanic current up to 990 uA, which is applied percutaneously with an acupuncture needle connected to the cathode. Although it is used in tendinopathies, trigger points and muscle injuries, among other conditions, its bases are mostly empirical and there is lack of evidence.

Ischemic compression is a manual therapy that is usually applied in muscle pain.

Myofascial Pain Syndrome (MPS) usually presents painful myofascial trigger points (MTrPs). One methodology used to quantify the pain in MPS is the algometry, which measures the pressure pain threshold (PPT).

The aim of this study was to compare the effects of MEP® with ischemic compression on MTrPs with algometry.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Between 18 to 30 years old.
* Who referred MTrP in the upper trapezious.
* PPT equal or less than 3 KgF/cm2

Exclusion Criteria:

* Being pregnant.
* Taking analgesic medication at least 24 hours before the intervention.
* Being in physical therapy treatment.
* Needle phobia.

Primary outcomes:
measure: Preasure Pain Threshold (PPT)
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Ciudad Autónoma de Buenos Aire
country: Argentina
facility: Oscar Ronzio
state: Caba
Study officials:
affiliation: I.U. Fundación H.A. Barceló - U. Maimónides - U. Nacional Arturo Jauretche
name: Oscar Ronzio
role: STUDY_DIRECTOR
References: